MX2021001544A - Uso de lc-ms/ms para cuantificar biomarcadores proteicos. - Google Patents

Uso de lc-ms/ms para cuantificar biomarcadores proteicos.

Info

Publication number
MX2021001544A
MX2021001544A MX2021001544A MX2021001544A MX2021001544A MX 2021001544 A MX2021001544 A MX 2021001544A MX 2021001544 A MX2021001544 A MX 2021001544A MX 2021001544 A MX2021001544 A MX 2021001544A MX 2021001544 A MX2021001544 A MX 2021001544A
Authority
MX
Mexico
Prior art keywords
protein biomarkers
quantitate protein
quantitate
biomarkers
abundance
Prior art date
Application number
MX2021001544A
Other languages
English (en)
Inventor
Ning Li
Yen E Sook
Haibo Qiu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021001544A publication Critical patent/MX2021001544A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Optics & Photonics (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)

Abstract

La presente descripción proporciona métodos y composiciones para la determinación de la abundancia y/o concentración de biomarcadores proteicos en una muestra biológica.
MX2021001544A 2018-08-08 2019-08-07 Uso de lc-ms/ms para cuantificar biomarcadores proteicos. MX2021001544A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715973P 2018-08-08 2018-08-08
PCT/US2019/045494 WO2020033537A1 (en) 2018-08-08 2019-08-07 Use of lc-ms/ms to quantitate protein biomarkers

Publications (1)

Publication Number Publication Date
MX2021001544A true MX2021001544A (es) 2021-04-13

Family

ID=67809655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001544A MX2021001544A (es) 2018-08-08 2019-08-07 Uso de lc-ms/ms para cuantificar biomarcadores proteicos.

Country Status (13)

Country Link
US (2) US11592449B2 (es)
EP (1) EP3833775A1 (es)
JP (2) JP7419340B2 (es)
KR (1) KR20210043589A (es)
CN (1) CN112888793A (es)
AU (1) AU2019318070A1 (es)
BR (1) BR112021001372A2 (es)
CA (1) CA3107631A1 (es)
EA (1) EA202190355A1 (es)
IL (1) IL280382A (es)
MX (1) MX2021001544A (es)
SG (1) SG11202100834SA (es)
WO (1) WO2020033537A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012032206A2 (pt) * 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
EP3151012B1 (en) * 2010-09-21 2018-03-21 Proteomics International Pty Ltd Biomarkers associated with diabetic nephropathy
WO2012111249A1 (ja) 2011-02-14 2012-08-23 学校法人麻布獣医学園 質量分析法における質量変化を検出する方法及び安定同位体標識タンパク質の絶対量の定量方法
WO2013151726A1 (en) * 2012-04-05 2013-10-10 Integrated Diagnostics, Inc. Srm methods in alzheimer's disease and neurological disease assays
CA2893158A1 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
DK2962100T3 (da) 2013-02-28 2021-11-01 Caprion Proteomics Inc Tuberkulosebiomarkører og anvendelser deraf
EP2821076A1 (en) 2013-07-02 2015-01-07 Stallergenes Sa C1q as a therapeutic agent of allergy and/or asthma
WO2015103645A2 (en) * 2014-01-06 2015-07-09 Expression Pathology, Inc. Srm assay for pd-l1
WO2017026241A1 (ja) 2015-08-07 2017-02-16 国立大学法人愛媛大学 質量分析を用いたｂ型肝炎ウイルスの測定方法
EP3352859B1 (en) 2015-09-24 2020-09-23 Expression Pathology, Inc. Quantifying met protein for cancer treatment
EP3571222A4 (en) * 2017-01-19 2021-06-16 Cedars-Sinai Medical Center HIGHLY MULTIPLEXED MASS SPECTROMETRY-BASED PROCESSES ALLOWING THE MEASUREMENT OF 72 HUMAN PROTEINS
EP3521828A1 (en) 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema

Also Published As

Publication number Publication date
US20200064355A1 (en) 2020-02-27
BR112021001372A2 (pt) 2021-05-04
US11592449B2 (en) 2023-02-28
JP2024032761A (ja) 2024-03-12
KR20210043589A (ko) 2021-04-21
WO2020033537A1 (en) 2020-02-13
CN112888793A (zh) 2021-06-01
JP2021532360A (ja) 2021-11-25
US20230366888A1 (en) 2023-11-16
JP7419340B2 (ja) 2024-01-22
AU2019318070A1 (en) 2021-02-18
EA202190355A1 (ru) 2021-05-25
IL280382A (en) 2021-03-01
CA3107631A1 (en) 2020-02-13
SG11202100834SA (en) 2021-02-25
EP3833775A1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
WO2020123316A3 (en) Methods for determining a location of a biological analyte in a biological sample
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
SG11202012585YA (en) Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
EP4345159A3 (en) Methods for trapping and barcoding discrete biological units in hydrogel
MX2022006655A (es) Uso de nucleosomas libres de celulas como biomarcadores.
EA201892491A1 (ru) Пцр в реальном времени с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) для анализа злокачественных новообразований
MX2018009505A (es) Metodo para determinar helicobacter pylori.
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
WO2019066572A3 (en) Method and device for analyzing target analyte in sample
MX2022000627A (es) Metodo para determinar al menos un parametro de una composicion de muestra que comprende acido nucleico, tal como arn, y opcionalmente particulas.
EP3936522A4 (en) METHOD FOR IMMUNOLOGICAL ANALYSIS OF ß-D-GLUCANE IN A BIOLOGICAL SAMPLE AND ß-D-GLUCANE ANALYSIS KIT
EP3832306A4 (en) METHOD FOR IMMUNOLOGICAL ANALYSIS OF (1?3)-?-D-GLUCANE IN A BIOLOGICAL SAMPLE, KIT FOR ANALYSIS OF (1?3)-?-D-GLUCANE, ?AND ALKALINE PRE-TREATMENT SOLUTION FOR BIOLOGICAL SAMPLE TO BE USED IN THE IMMUNOLOGICAL TESTING METHOD OF (1?3)-?-D-GLUCANE
MX2014000378A (es) Analisis rapdo y preciso de la sialilacion de proteinas.
MX2021001544A (es) Uso de lc-ms/ms para cuantificar biomarcadores proteicos.
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
MX2020011631A (es) Ensayo de acetaminofeno.
MX2022012840A (es) Inmunoensayo de desactivacion de fluorescencia.
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.
SA520411045B1 (ar) طاقم وطريقة لتحديد وجود أنواع كبريتيد حمضي باستخدام صبغة معقد فلزي